A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-08-07
AEs
3
Serious
0
Dropout signal
–
Adverse events
severe
assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 43); relationship: not assessed
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-04-16 (study day 238); relationship: N
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-05-03 (study day 255); relationship: N
Data queries
No data queries.